

Arkansas Medicaid DUR Board Meeting Minutes

Date / Time:	October 15, 2025 8:30 AM– 12:30 PM Central		Location:	ZOOM webinar	
Chair:	Cindi Pearson, Pharm.D.		Reports:	Jeniffer Martin, Pharm.D. Prime Therapeutics Karen Evans, P.D. Prime Therapeutics Allison Sweeney, Pharm.D. Prime Therapeutics	
Attendance		Panelist (voting members)		Panelist (non-voting members)	Organization
		Geri Bemberg, Pharm.D.	X	Barry Fielder, Pharm.D.	ATC
	X	Clint Boone, Pharm.D.	X	Lora Ertmoed, Pharm.D.	Empower
	X	Ashley Crawley, Pharm.D.	X	Jon Delarosa, Pharm.D.	Empower
	X	Gabriella Douglass, Pharm.D.	X	Lauren Jimerson, Pharm.D.	Summit
	X	Trenton Dunn, Pharm.D.	X	Jessica Lawson, Pharm.D.	CareSource
	X	Lana Gettman, Pharm.D.		Jennifer Chapin, Pharm.D.	CareSource
	X	John Dawson Irvin, M.D.	X	Ifeyinwa Onowu, Pharm.D.	CareSource
	X	Michael Mancino, M.D.	X	Cindi Pearson, Pharm.D.	DHS, DUR Chair
	X	Melissa Max, Pharm.D.	X	Cynthia Neuhofer, Pharm.D.	DHS pharmacy
	X	Brenna Neumann, Pharm.D.		Elizabeth Pitman	DHS DMS director
		Daniel Pace, M.D.		William Golden, M.D.	DHS advisor
	X	Paula Podrazik, M.D.	X	Christopher Smith, M.D.	DHS advisor
	X	Chad Rodgers, M.D.	X	Shane David, Pharm.D.	ADH advisor
		Shailendra Singh, MBBS, FACP	X	Karen Evans, P.D.	Prime Therapeutics
		Open M.D. position	X	Jeniffer Martin, Pharm.D.	Prime Therapeutics
			X	Lesley Irons, Pharm.D.	Prime Therapeutics
				Linsey Gillam, Pharm.D.	Prime Therapeutics
			X	Alyson Greenwood, Pharm.D.	Prime Therapeutics
			X	Allison Sweeney, Pharm.D.	Prime Therapeutics
Call to order		Meeting held virtually by ZOOM webinar. A quorum was present, and the chair called the meeting to order at 8:58am.			
Public comments		1) Andrew Delgado, PharmD, PhD—Bristol-Myers Squibb (SOTYKTU) 2) Jamie Tobitt, PharmD—Apellis Pharmaceuticals (EMPAVELI) 3) Erik Schindler, PharmD, BCPS—Sanofi (DUPIXENT) 4) Ryan Miller, MS, CGD—PTC Therapeutics (SEPHIENCE) 5) Shari Orbach, MPH—Madrigal Pharmaceuticals (REZDIFFRA) 6) Chair read comments from Dr. Keith Coward on MASH			
Announcements		1. Dr. Douglass had a conflict of interest with the Hepatitis C class and did not vote, and all other Board members had no conflict of interest. Dr. Pearson, Dr. Martin, Dr. Evans, Dr. Sweeney and Dr. Greenwood had no conflict of interest. 2. Electronic PA report for September 2025 by Dr. Pearson 3. Quarterly provider newsletter—  Arkansas Medicaid Quarterly Newsletter (4. New medications following the oncology policy a. Ibtrozi (taletrectinib) capsule b. Modeyso (dordaviprone) capsule c. Hernexeos (zongertinib) tablet d. Faslodex (fulvestrant) injection 5. System edits updates from previous meeting			

Arkansas Medicaid DUR Board Meeting Minutes

	6. Update on Khindivi (hydrocortisone) solution.
Minutes	Motion to approve July 2025 DUR meeting minutes as presented was made by Dr. Mancino, second by Dr. Rodgers. All voting members present voted for approval of the minutes as written. Motion passed.
Reports	- Dr. Sweeney from Prime Therapeutics gave the fee-for-service beneficiary lock-in status, and Top 25 reports. She also presented RDUR criteria for voting for the next quarter. - November 2025—Rescue MDI (≥ 2 in 90 days without a maintenance inhaler) - December 2025—Non-compliance with atypical antipsychotics (oral and IV), 10-day gap - January 2026—Concurrent use of opioids and sedative hypnotics and Non-compliance with antiretrovirals, 3-day gap ACTION: Motion was made by Dr. Rodgers for the above criteria; second by Dr. Podrazik and Dr. Crawley. All other members present voted for the motion. Motion passed. - Dr. Sweeney from Prime Therapeutics provided an RDUR Outcomes Analysis for July 2024-December 2024 - Dr. Irvin asked if this data included all prescriber types, and Dr. Sweeney confirmed it was all types. - Dr. Pearson presented the PASSE ProDUR report for April through June 2025. - Dr. Evans from Prime Therapeutics presented the FFS ProDUR report for July through September 2025
PDL Class Review	1) <u>Tetracyclines</u> Dr. Martin presented a PowerPoint with the following information. - Overview of medications with information product strengths and dosage forms - Overview of mechanism of action - Drug class warnings - Types of infections treated with the tetracycline class - Treatment considerations - Claims summary from 7/1/2024-6/30/2025 DISCUSSION: Dr. Irvin noted that he uses doxycycline quite a bit, and Dr. Rodgers stated he uses doxycycline and minocycline. ACTION: Motion was made by Dr. Irvin to include doxycycline 100 mg as a preferred option with additional preferred options decided by the cost committee; second by Dr. Douglass. All other members in attendance voted for the motion. Motion passed. 2) <u>Topical Antibiotics</u> Dr. Martin presented a PowerPoint with the following information. - Overview of topical antibiotics with FDA-approved indications and microorganisms impacted - Drug class warnings - Treatment guidelines - Claims summary from 7/1/2024-6/30/2025 DISCUSSION: Dr. Rodgers noted he mostly uses mupirocin, and Dr. Irvin does use mupirocin but some gentamicin. ACTION: Motion was made by Dr. Irvin to make mupirocin a preferred option with additional preferred options decided by the cost committee; second by Dr. Podrazik. All other members in attendance voted for the motion. Motion passed.

Arkansas Medicaid DUR Board Meeting Minutes

3) Butalbital Agents (without codeine)

Dr. Martin presented a PowerPoint with the following information.

- a) Overview of medications with strengths and dosage forms
- b) Symptoms for tension headache
- c) Drug class warnings
- d) Treatment guidelines
- e) Claims summary from 7/1/2024-6/30/2025

DISCUSSION:

Dr. Douglass asked if there is any way to note if the claims are for unique patients or are some claims for patients using the medication chronically. Dr. Martin confirmed that the utilization was every claim and there could be some one-time claims and others are refilled. Dr. Douglass wondered if the medications were being used appropriately. Dr. Newmann contacted the Chair after the meeting with concerns for this class as well. The Chair instructed the RDUR pharmacist to run reports on utilization and develop a review of the overutilizers.

ACTION:

Motion was made by Dr. Mancino for butalb/apap/caffeine 50-325-40 tablets to be a preferred option with additional preferred options decided by the cost committee; second by Dr. Irvin. All other members in attendance voted for the motion. Motion passed.

4) Androgen Agents

Dr. Martin presented a PowerPoint with the following information.

- a) Overview of medications with strengths and dosage forms along with advantages and disadvantages
- b) Clinical evidence with the TRAVERSE study
- c) Recent FDA labeling updates
- d) Treatment Recommendations
- e) Claims summary from 7/1/2024-6/30/2025

DISCUSSION:

None

ACTION:

Motion was made by Dr. Irvin for one topical and one injection formulation as preferred options with additional preferred options decided by the cost committee; second by Dr. Mancino. All other members in attendance voted for the motion. Motion passed.

5) Targeted Immunomodulators

Dr. Martin presented a PowerPoint with the following information

- a) Discussed DUR Board reviews this year and asked permission to send to the cost committee for review.
- b) Claims summary from 7/1/2024-6/30/2025

DISCUSSION:

None

ACTION:

Motion was made by Dr. Boone to submit the TIMs class to the cost committee for review; second by Dr. Podrazik. All other members in attendance voted for the motion. Motion passed.

Arkansas Medicaid DUR Board Meeting Minutes

	6) <u>Classes without changes</u> • ALZHEIMER'S AGENTS • ANTI-PARKINSON'S AGENTS • BOWEL PREP AGENTS AND KITS • HEPATITIS C MEDICATIONS • HMG-COA REDUCTASE INHIBITORS • IMMUNE GLOBULINS • NEUROPATHIC PAIN AGENTS • PENICILLAMINE/CYSTINE-DEPLETING AGENTS • PHOSPHATE REMOVING AGENTS • PLATELET AGGREGATION INHIBITORS • PROTON PUMP INHIBITORS • SEDATIVE HYPNOTICS DISCUSSION: No comments ACTION: Motion was made by Dr. Irvin to remove discontinued medications and keep the current preferred options; second by Dr. Gettman. All other members in attendance voted for the motion except Dr. Douglass due to conflict of interest on Hepatitis C meds. Motion passed.
Disease States	1) <u>BULLOUS PEMPHIGOID</u> <u>Dr. Pearson presented the following:</u> • Information on Bullous Pemphigoid with clinical presentation • Treatment recommendations from the <i>Journal of the European Academy of Dermatology and Venerology</i> 2022 • Clinical information from the package insert for DUPIXENT • Recommended approval criteria and renewal requirements for treatment of Bullous Pemphigoid DISCUSSION: Dr. Irvin stated that there aren't many dermatologists in his area, and many don't take Medicaid. Dr. Irvin stated that anyone can do a punch biopsy in a clinic. The Chair stated that we can remove the dermatologist requirement since a biopsy will be needed for diagnosis confirmation. Dr. Podrazik had concerns about no dermatologist, but she agreed that as long as a biopsy confirms the diagnosis we can amend the criteria. ACTION: Motion was made by Dr. Irvin to approve criteria as amended; second by Dr. Mancino. All other members in attendance voted for the motion. Motion passed.
Changes to existing criteria or edits	1) <u>EMPAVELI (pegcetacoplan) vial</u> <u>Dr. Pearson provided the following:</u> • Clinical information from the package insert for EMPAVELI • Estimated reimbursement rate • Information on Primary Immune-Complex Membranoproliferative Glomerulonephritis • Recommended updates to approval criteria and renewal requirements DISCUSSION: None ACTION: Motion was made by Dr. Mancino to approve criteria as presented; second by Dr. Irvin. All other members in attendance voted for the motion. Motion passed.

Arkansas Medicaid DUR Board Meeting Minutes

	2) <u>WEGOVY (semaglutide) injection</u> <u>Dr. Pearson provided the following:</u> • Clinical information from the package insert for WEGOVY • Estimated reimbursement rate • Information on Metabolic Dysfunction-Associated Steatohepatitis • Recommended approval criteria and renewal requirements DISCUSSION: None ACTION: Motion was made by Dr. Irvin to accept the criteria as presented; second by Dr. Podrazik. All other members in attendance voted for the motion. Motion passed. 3) <u>REZDIFFRA (resmetirom) tablet</u> <u>Dr. Pearson provided the following:</u> • Clinical information from the package insert for REZDIFFRA • Estimated reimbursement rate • Recommended updates to approval criteria and renewal requirements DISCUSSION: None ACTION: Motion was made by Dr. Podrazik to accept the criteria as presented; second by Dr. Irvin. All other members in attendance voted for the motion. Motion passed.
New Business	1) <u>SEPHIENCE (sepiapterin) oral powder</u> <u>Dr. Pearson provided the following:</u> • Clinical information from the package insert for SEPHIENCE • Estimated reimbursement rate • Information on Hyperphenylalaninemia and Phenylketonuria • Recommended approval criteria and renewal requirements DISCUSSION: Dr. Mancino asked when did the research see a significant difference between placebo and the medication. Dr. Mancino was concerned that 30 days on the initial approval would not be enough to see a response. The Chair noted that we typically see a response on Kuvan in a short time, but this product appears different according to the data. Dr. Mancino suggested changing the initial PA to 90 days. ACTION: Motion was made by Dr. Mancino to accept the criteria as amended; second by Dr. Irvin. All other members in attendance voted for the motion. Motion passed. 2) <u>HARLIKU (nitisinone) tablet</u> <u>Dr. Pearson provided the following:</u> • Clinical information from the package insert for HARLIKU • Estimated reimbursement rate • Information on Alkaptonuria • Recommended approval criteria and renewal requirements

Arkansas Medicaid DUR Board Meeting Minutes

DISCUSSION:

The Chair amended the criteria by adding a 90 day initial PA duration.

ACTION:

Motion was made by Dr. Irvin to accept the criteria as amended; second by Dr. Podrazik. All other members in attendance voted for the motion. Motion passed.

3) EKTERLY (sebetralstat) tablet

Dr. Pearson provided the following:

- Clinical information from the package insert for EKTERLY
- Estimated reimbursement rate
- Information on Hereditary Angioedema
- Acute treatment utilization 1/1/2024-9/16/2025
- Recommended approval criteria and renewal requirements

DISCUSSION:

None

ACTION:

Motion was made by Dr. Irvin to accept the criteria as presented; second by Dr. Podrazik. All other members in attendance voted for the motion. Motion passed.

4) ANDEMBRY (garadacimab) injection and DAWNZERO (donidalorsen) injection

Dr. Pearson provided the following:

- Clinical information from the package insert for ANDEMBRY and DAWNZERO
- Estimated reimbursement rate
- Prophylaxis treatment utilization 1/1/2024-9/16/2025
- Recommended approval criteria and renewal requirements

DISCUSSION:

None

ACTION:

Motion was made by Dr. Mancino to accept the criteria as presented; second by Dr. Podrazik. All other members in attendance voted for the motion. Motion passed.

5) ANZUPGO (delgocitinib) cream

Dr. Pearson provided the following:

- Clinical information from the package insert for ANZUPGO
- Estimated reimbursement rate
- Information on Chronic Hand Eczema
- Recommended approval criteria and renewal requirements

DISCUSSION:

None

ACTION:

Motion was made by Dr. Irvin to accept the criteria as presented; second by Dr. Podrazik. All other members in attendance voted for the motion. Motion passed.

Arkansas Medicaid DUR Board Meeting Minutes

	6) <u>EGRIFTA WR and SV (tesamorelin) vial</u> <u>Dr. Pearson provided the following:</u> • Clinical information from the package insert for EGRIFTA WR and SV • Estimated reimbursement rate • Information on Lipodystrophy • Recommended approval criteria and renewal requirements DISCUSSION: Dr. Douglass stated she liked the requirement to measure visceral adipose tissue. The integrase inhibitors do have weight gain but not the lipodystrophy pattern. Measuring the circumference will be a challenge since weight gain happens, but the CT scan will be good to include in the criteria. Dr. Douglass did not recommend any changes. ACTION: Motion was made by Dr. Mancino to accept the criteria as presented; second by Dr. Gettman. All other members in attendance voted for the motion. Motion passed. 7) <u>BRINSUPRI (brensocatib) tablet</u> <u>Dr. Pearson provided the following:</u> • Clinical information from the package insert for BRINSUPRI • Estimated reimbursement rate • Information on Non-Cystic Fibrosis Bronchiectasis • Recommended approval criteria and renewal requirements DISCUSSION: None ACTION: Motion was made by Dr. Max to accept the criteria as presented; second by Dr. Irvin. All other members in attendance voted for the motion. Motion passed. 8) <u>ZELSUVMI (berdazimer) gel</u> <u>Dr. Pearson provided the following:</u> • Clinical information from the package insert for ZELSUVMI • Estimated reimbursement rate • Information on Molluscum Contagiosum • Recommended approval criteria and renewal requirements DISCUSSION: None ACTION: Motion was made by Dr. Irvin to accept the criteria as presented; second by Dr. Douglass. All other members in attendance voted for the motion. Motion passed.
Board comments	Dr. Boone asked about dosage changes requiring a PA. Dr. Pearson stated she would discuss the requirement with Prime Therapeutics.
Adjourn	Adjourned at 12:15pm